Lilly's New Weight-loss Pill Shows Promise in Study

A recent study shows patients did not regain significant weight after switching from injectable GLP-1 medication to Eli Lilly's new weight-loss pill, Foundayo. Transitioning from Novo Nordisk's Wegovy led to minimal weight gain, while switching from Lilly's Zepbound resulted in an average gain of 11 pounds.

Devdiscourse News Desk | Updated: 13-05-2026 10:29 IST | Created: 13-05-2026 10:29 IST

Lilly's New Weight-loss Pill Shows Promise in Study — This image is AI-generated and does not depict any real-life event or location. It is a fictional representation created for illustrative purposes only.

Eli Lilly's new weight-loss pill Foundayo exhibited promising results in a recent study. Patients transitioning from long-term injectable GLP-1 medications did not experience substantial weight gain after a year on the pill.

According to study results presented at an obesity conference, those who switched from Novo Nordisk's Wegovy to Foundayo regained merely 2 pounds on average. However, patients transitioning from Lilly's more potent Zepbound injectable saw an average weight gain of 11 pounds.

This study underscores the potential of oral medications in long-term weight management, offering alternatives to injectables with comparable efficacy.

(With inputs from agencies.)